Saturday February 24, 2018

Intake of Coffee can Reduce the risk of Death for Kidney Patients

Drinking Coffee may increase the lifespan of patients with chronic kidney disease.

0
//
55
Drinking Coffee reduces mortality in Kidney patients
Drinking Coffee reduces mortality in Kidney patients. Pixabay
Republish
Reprint
  • Want to live longer? Charge up on your cup of coffee. According to a study, caffeine consumption may prolong the lifespan of patients with chronic kidney disease (CKD).

Drinking coffee can Reduce mortality 

The findings showed a dose-dependent inverse association between caffeine and all-cause mortality.

People who had the highest intake of coffee had 24 percent lower risks of dying, while those in the second, third quartile of caffeine consumption had 12 percent and 22 percent lower risk.

“These results suggest that advising patients with CKD to drink more caffeine may reduce their mortality. This would represent a simple, clinically beneficial, and inexpensive option,” said Miguel Bigotte Vieira from Centro Hospitalar Lisboa Norte, in Portugal.

However, “this benefit should ideally be confirmed in a randomised clinical trial”, Vieira added.

For the study, the team examined the association of caffeine consumption with mortality among 2328 patients with CKD. The results will be presented at the ongoing ASN Kidney Week 2017 in New Orleans.

Moreover, this observational study cannot prove that drinking coffee reduces the risk of death in patients with CKD, but only suggests the possibility of such a protective effect, Vieira stressed.

Drinking coffee can also reduce diabetes risk, revealed a reported in the American Chemical Society Journal of Natural Products.(IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Common BP Drug May Prevent Onset Of Type 1 Diabetes

For the study, published in the Journal of Clinical Investigation, the team used a supercomputer, on the lab bench, in mice, and in humans

0
//
20
Type 1 Diabetes

A drug commonly used to control high blood pressure may be also effective in preventing the onset of Type 1 diabetes in up to 60 percent of those at risk, researchers say.

The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children and is also on the World Health Organization’s list of essential drugs.

Methyldopa was found to block a molecule called DQ8 — found in some 60 percent at the risk of getting Type 1 diabetes — which significantly increases the chance of getting the disease.

Blocking specifically the DQ8 molecule could also block the onset of the disease, the study found.

 

ALSO READ: Eat According to Your Blood Type and See the Benefits Yourself!

“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, Associate Professor of medicine at University of Colorado – Anschutz.

“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at the risk for the disease. This is very significant development,” Michels added.

Type 1 Diabetes

For the study, published in the Journal of Clinical Investigation, the team used a supercomputer, on the lab bench, in mice, and in humans.

They found that methyldopa not only blocked DQ8, but it did not also harm the immune function of other cells like many immunosuppressant drugs do.

ALSO READ: Diabetes can hamper your reproductive health

“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes. The goal, with this drug, is to delay or prevent the onset of the disease among those at risk,” Michels said.

The drug is taken orally, three times a day.

Besides, diabetes, the same approach of blocking specific molecules can be used in other autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others, the researchers noted. (IANS)

Next Story